Coherus Oncology, Inc. (CHRS)

1.02 -0.05 (-4.67%) USD  |  NASDAQ  |  Oct 16, 13:29
More

Coherus Oncology SG&A Expense (TTM) : 92.60M for June 30, 2026

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 92.60M
March 31, 2026 97.68M
December 31, 2025 100.60M
September 30, 2025 118.29M
June 30, 2025 128.10M
March 31, 2025 137.23M
December 31, 2024 167.74M
September 30, 2024 175.94M
June 30, 2024 189.42M
March 31, 2024 199.39M
December 31, 2023 192.02M
September 30, 2023 196.14M
June 30, 2023 192.75M
March 31, 2023 198.88M
December 31, 2022 198.48M
September 30, 2022 194.91M
June 30, 2022 190.01M
March 31, 2022 179.08M
December 31, 2021 169.71M
September 30, 2021 157.35M
June 30, 2021 149.41M
March 31, 2021 143.12M
December 31, 2020 139.08M
September 30, 2020 137.46M
June 30, 2020 137.30M
Date Value
March 31, 2020 139.70M
December 31, 2019 137.04M
September 30, 2019 134.81M
June 30, 2019 128.35M
March 31, 2019 110.28M
December 31, 2018 94.18M
September 30, 2018 75.32M
June 30, 2018 63.94M
March 31, 2018 69.08M
December 31, 2017 71.30M
September 30, 2017 71.62M
June 30, 2017 71.28M
March 31, 2017 59.00M
December 31, 2016 51.60M
September 30, 2016 47.28M
June 30, 2016 43.80M
March 31, 2016 41.35M
December 31, 2015 36.05M
September 30, 2015 31.26M
June 30, 2015 25.07M
March 31, 2015 20.23M
December 31, 2014 17.56M
September 30, 2014 13.88M
June 30, 2014 12.25M
March 31, 2014 9.597M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Enanta Pharmaceuticals, Inc. 37.75M
ACADIA Pharmaceuticals, Inc. 620.29M
Alnylam Pharmaceuticals, Inc. 1.318B
Anika Therapeutics, Inc. 52.67M
Savara, Inc. 56.71M